,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-04-16 07:24:00,St. Jude Medical Inc. ( STJ ) posted a 4.3% rise in adjusted net earnings per share to 96 cents for the first quarter of 2014 from 92 cents a year-ago.,0.9579243659973145,0.024503914639353752,0.017571797594428062,positive,0.9334204792976379
1,2014-04-16 07:24:00,"With this, this St. Paul, MN-based medical device maker beat the Zacks Consensus Estimate by a penny and met its own guidance of 94 and 96 cents per share for the quarter.",0.9474831223487854,0.026238758116960526,0.026278048753738403,positive,0.9212443828582764
2,2014-04-16 07:24:00,"Reported earnings were $249 million or 86 cents per share in the quarter, compared with $223 million or 78 cents per share in the comparable quarter of 2013.",0.354873389005661,0.6061995625495911,0.03892705589532852,negative,-0.25132617354393005
3,2014-04-16 07:24:00,"Revenues grew about 2.0% to $1,363 million for the quarter, exceeding the Zacks Consensus Estimate of $1,355 million as well as the company's own guided range of 1,280 to $1,360 million.",0.9582933783531189,0.020792856812477112,0.02091384120285511,positive,0.937500536441803
4,2014-04-16 07:24:00,Unfavorable foreign currency translation reduced revenues by roughly $25 million.,0.016452277079224586,0.9735097289085388,0.010037945583462715,negative,-0.9570574760437012
5,2014-04-16 07:24:00,"At constant currency, net revenues increased 4% over the prior-year quarter.",0.9590809345245361,0.019528347998857498,0.0213907640427351,positive,0.9395526051521301
6,2014-04-16 07:24:00,Revenues from the U.S. inched up 0.6% to $644 million while international revenues increased 3.0% to $719 million.,0.9548031091690063,0.023118676617741585,0.02207818068563938,positive,0.9316844344139099
7,2014-04-16 07:24:00,"In the Cardiac Rhythm Management (CRM) division, revenues went up 1.3% to $687 million, while it increased 3% excluding the impact of foreign currency.",0.9590516686439514,0.021014273166656494,0.019934069365262985,positive,0.9380373954772949
8,2014-04-16 07:24:00,U.S. revenues upped 1.4% to $367 million while international revenues zoomed only 1.3% to $320 million.,0.9468076825141907,0.03238046541810036,0.02081192657351494,positive,0.9144272208213806
9,2014-04-16 07:24:00,"In the CRM division, implantable cardiac defibrillator (ICD) revenues escalated 2.1% (3% in constant-currency) to $436 million.",0.9466527104377747,0.03439515084028244,0.01895214058458805,positive,0.9122575521469116
10,2014-04-16 07:24:00,"Meanwhile, pacemaker revenues were flat at $251 million compared with the prior year quarter.",0.016949722543358803,0.9690311551094055,0.014019052498042583,negative,-0.9520814418792725
11,2014-04-16 07:24:00,"At constant-currency, pacemaker revenues rose 2% in the quarter.",0.9568746089935303,0.018281159922480583,0.024844208732247353,positive,0.9385934472084045
12,2014-04-16 07:24:00,"In the Atrial Fibrillation (AF) division, revenues scaled up 7.7% to $251 million, while at constant currency it increased 10% over the first quarter of 2013.",0.9568028450012207,0.017349591478705406,0.025847556069493294,positive,0.9394532442092896
13,2014-04-16 07:24:00,U.S. revenues rose 5.5% to $96 million while international revenues grew 9.2% to $155 million.,0.9543948769569397,0.022239500656723976,0.023365577682852745,positive,0.9321553707122803
14,2014-04-16 07:24:00,"In the Cardiovascular division, revenues slid 0.6% to $326 million in the quarter but rose 2% at constant-currency.",0.019886497408151627,0.9684928059577942,0.01162067148834467,negative,-0.9486063122749329
15,2014-04-16 07:24:00,Revenues from the U.S. inched up 0.9% to $114 million but revenues from the international market fell 1.4% to $212 million.,0.10689868032932281,0.8758423924446106,0.017258919775485992,negative,-0.768943727016449
16,2014-04-16 07:24:00,"In the cardiovascular division, vascular product revenues edged up roughly 1% to $172 million at constant currency.",0.9570179581642151,0.01989263854920864,0.02308945171535015,positive,0.9371253252029419
17,2014-04-16 07:24:00,"Meanwhile, structural heart product revenues were almost flat at $154 million but rose 3% in constant currency, for the quarter.",0.703772783279419,0.21455320715904236,0.08167403936386108,positive,0.4892195761203766
18,2014-04-16 07:24:00,"In the Neuromodulation division, revenues were flat at $99 million in the first quarter, both on a reported and constant-currency basis.",0.015501088462769985,0.9615340828895569,0.02296489290893078,negative,-0.9460330009460449
19,2014-04-16 07:24:00,Revenues from the U.S. ebbed 9.5% to $67 million but revenues from the international market improved 28% to $32 million.,0.9491238594055176,0.030571123585104942,0.02030503749847412,positive,0.9185527563095093
20,2014-04-16 07:24:00,"St. Jude Medical had cash and cash equivalents of $1,446 million as of Mar 29, 2014, up 5.3% from $1,373 million as of Dec 28, 2013.",0.9559963345527649,0.021542707458138466,0.022461019456386566,positive,0.9344536066055298
21,2014-04-16 07:24:00,"Total debt rose 9.2% to $3,910 million as of Mar 29, 2014 compared with $3,580 million as of Dec 28, 2013.",0.9482418298721313,0.025398703292012215,0.02635951153934002,positive,0.9228430986404419
22,2014-04-16 07:24:00,"Consequently, debt-to-capitalization increased 320 basis points to 48.0% from 44.8% as of Dec 28, 2013.",0.9595552682876587,0.020278792828321457,0.02016589604318142,positive,0.9392764568328857
23,2014-04-16 07:24:00,"For the second quarter of 2014, St. Jude Medical expects revenues in the range of $1,380 million to $1,460 million while the company anticipates adjusted net earnings per share to lie between 99 cents and $1.01 for the quarter.",0.11634919792413712,0.018725816160440445,0.864924967288971,neutral,0.09762337803840637
24,2014-04-16 07:24:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the quarter are pegged at $1.00 and $1,441 million.",0.025197017937898636,0.024041155353188515,0.9507618546485901,neutral,0.0011558625847101212
25,2014-04-16 07:24:00,"For full year 2014, St. Jude Medical upgraded its revenues guidance to the range of $5,610 to $5,760 million from the prior range of $5,600 million to $5,750 million.",0.9325768351554871,0.01961192861199379,0.047811221331357956,positive,0.9129648804664612
26,2014-04-16 07:24:00,It also upgraded its adjusted earnings per share guidance to $3.95-$4.00 from the prior range of $3.94-$3.99.,0.9361036419868469,0.020884614437818527,0.04301178827881813,positive,0.9152190089225769
27,2014-04-16 07:24:00,"The current Zacks Consensus Estimates for earnings per share and revenues for the year are pegged at $3.98 and $5,692 million.",0.026914037764072418,0.029752610251307487,0.9433333873748779,neutral,-0.0028385724872350693
28,2014-04-16 07:24:00,"We are impressed with St. Jude Medical's first quarter results, which topped estimates at both fronts.",0.9387262463569641,0.016199544072151184,0.04507420212030411,positive,0.9225267171859741
29,2014-04-16 07:24:00,"Moreover, the company's upgraded earnings and revenues guidance is encouraging.",0.9516851902008057,0.016935933381319046,0.03137898072600365,positive,0.9347492456436157
30,2014-04-16 07:24:00,"Currently, St. Jude carries a Zacks Rank #2 (Buy).",0.2735719382762909,0.022090885788202286,0.7043371796607971,neutral,0.2514810562133789
31,2014-04-16 07:24:00,"Other stocks in the medical products industry that are also worth considering include Enzymotec Ltd. ( ENZY ), Edwards Lifesciences Corp. ( EW ), and Owens & Minor Inc. ( OMI ).",0.07108701020479202,0.005371578969061375,0.9235414266586304,neutral,0.06571543216705322
32,2014-04-16 07:24:00,"Enzymotec carries a Zacks Rank #1 (Strong Buy), while both Edwards Lifesciences Corp. and Owens & Minor retain a Zacks Rank #2 (Buy).",0.6448344588279724,0.019768444821238518,0.33539706468582153,positive,0.6250660419464111
33,2014-04-16 07:24:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
34,2014-04-16 07:24:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
